Logo

Asuragen Quantidex NGS RNA Lung Cancer Kit

Nov 01, 2016

Asuragen has launched the QuantideX NGS RNA Lung Cancer Kit, a next-generation sequencing panel that analyzes known gene fusions, 3' and 5' imbalance markers, exon skipping events, and mRNA expression levels in non-small cell lung cancer samples. The kit is optimized for use with low-quality samples and low input samples, including from formalin-fixed paraffin-embedded and fine needle aspirations. It has also been designed to work with Asuragen's Sample-Aware bioinformatics software. According to the company, the panel can detect fusions and splice variants at 5 percent cell fraction and 1 percent cell fraction, respectively. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.